

# 2014

Senate Bill 486 Evaluation Team  
**CONSUMER REPORT CARD**



**SUMMARY:**

The legislatively mandated deadline for report submission was July 1, 2014. There were 24 plans submitted to the State of California which posted them on their website for public consumption. These plans were read and graded by a 9-person evaluation team, scoring each plan based on published consumer criteria. There were:

- Four "A" grade plans;
- Three "B" grade plans;
- One "C" grade plan;
- One "D" grade plan; and
- Eighteen "F" grade plans.
- In addition, sixteen "F/Incomplete" grade plans were given for those manufacturers who did not submit plans by the legislatively mandated deadline of July 1 or did not submit plans whatsoever.

At least fourteen manufacturers resubmitted or retyped their 2010, 2011, 2012 or 2013 plans verbatim and those are indicated with an asterisk (\*). Plans that were submitted **after** the legislatively mandated July 1 deadline are marked with a (∞).

<u>Manufacturer</u>	<u>Score</u>	<u>Grade</u>
Abbvie*∞	94	A
Amgen*	90	A
AstraZeneca	14	F
Bayer	21	F
Biogen Idec	80	B
Bristol Meyers Squibb*		
Orencia	80	B
Other drugs	0	F
Drugs in trial	43	F
CSL Behring*	2	F
Dr. Reddy's Lab	9	F
Eisai*	62	D
Eli Lilly & Co.*	13	F
EMD Serono*	93	A
Genentech/Roche	46	F
GlaxoSmithKline	42	C
Grifols, Inc.	15	F
Janssen Biotech, Inc.	94	A
JHP	3	F
Merck *	32	F
Novartis*∞		
Signifor	75	B
All Others	15	F
Perrigo*	5	F
Pfizer	20	F
Sandoz*	3	F
Sanofi-Aventis*	47	F
Teva (Neuro)*	22	F
Teva (Others)*	17	F

**THE FOLLOWING DRUG MANUFACTURERS  
ARE IN VIOLATION OF STATE LAW DUE TO THE  
FACT THAT THEY DID NOT SUBMIT ANY PLANS  
TO THE STATE IN 2014 YET MAKE HOME  
INJECTABLE MEDICATION SUBJECT TO SB 486:**

<b><u>Manufacturer</u></b>	<b><u>Grade</u></b>
Biovitrium (no plan on file since law went into effect in 2010)	F
Baxter (last plan on file: 2012, authored in 2010)	F
Dey Pharmaceuticals (last plan on file: 2011)	F
Ferring Pharmaceuticals (last submitted in 2011)	F
Hospira (last plan on file: 2011- claim they are not subject to SB 486)	F
InterMune (last plan on file: 2011)	F
Ipsen (last plan on file: 2011)	F
Kadmon (last plan on file: 2013)	F
NPS (last plan on file: 2013)	F
Novo Nordisk (last plan on file: 2011)	F
Mallinckrodt (Questcor) Pharmaceuticals (no plan on file since law went into effect in 2010)	F
Salix (last plan on file: 2012)	F
Shire HGT (last plan on file: 2012)	F
Viro (last plan on file: 2013)	F
UCB, Inc. (last plan on file: 2012)	F
Zoegenix (no plan on file since law went into effect in 2010; manufacturer claims they have a proprietary “needle-fee” subcutaneous injection delivery system and aren’t subject to SB 486)	F